Phacilitate Leaders World

Conference speakers

Loading
Randy Schweickart

Randy Schweickart

Director of Engineering, Juno Therapeutics, Inc.

Randy Schweickart is currently a Director of Engineering in the Cell Therapy Technology and Platforms Department at Juno Therapeutics, a wholly owned subsidiary of Celgene Corp.  In this role he is responsible for the development and implementation of equipment and automation for CAR-T and TCR therapy manufacturing processes.  These activities are focused on both the transformation of current generation process equipment as well as advancement of next generation manufacturing plant concepts and process technologies.

Randy has over 25 years of equipment and automation design experience in the biopharmaceutical industry with prior positions at ICOS/CMC and Amgen.  He has been a key contributor in the pioneering of high productivity, manufacturing-scale, perfusion-based biomanufacturing processes and implementation of reconfigurable manufacturing plant concepts utilizing single-use systems and portable process equipment.

Prior experiences include designing equipment for Space Shuttle flight experiments and serving as a Principle Investigator in a microbiology microgravity experiment that flew on the final Columbia mission.  Randy has a B.S. degree in Civil Engineering from MIT and an M.S. degree in Mechanical Engineering from the Center for Biochemical Engineering at Duke University.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK